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Abstract: To investigate the effect of oligodeoxynucleotides (ODNs) on the differentiation 
of rat bone marrow mesenchymal stem cells (BMSCs) to osteoblasts, in order to find a 
candidate ODN with potential for the treatment of periodontitis, a series of ODNs were 
designed and selected to test their effect on the promotion of the differentiation of BMSCs 
to osteoblasts in vitro and on the repair of periodontal tissue in rats with periodontitis. It 
was found that MT01, one of the ODNs with the sequences of human mitochondrial DNA, 
stimulated the proliferation of BMSCs, the differentiation of BMSCs to osteoblasts and 
mRNA expression of bone-associated factors including Runx2, Osterix, OPG, RANKL and 
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collagen I in vitro. In vivo study showed that MT01 prevented the loss of alveolar bone in 
the rats with periodontitis and induced the production of proteins of OPG and Osterix in 
the bone tissue. These results indicated that MT01 could induce differentiation of BMSCs 
to osteoblasts and inhibit the alveolar bone absorption in rats with periodontitis. 
Keywords:  oligodeoxynucleotide; bone marrow mesenchymal stem cells; osteoblasts; 
differentiation; periodontitis 
 
1. Introduction 
Periodontitis is an inflammatory disease which manifests clinically as loss of the supporting 
periodontal tissues including the periodontal ligament, cementum and alveolar bone. Periodontal 
therapy is aimed at achieving the complete regeneration of these structures, especially the alveolar 
bone [1]. To date, several methods have been employed to achieve this goal, e.g., using various bone 
grafts, growth factors and barrier membranes [2,3]. Generally, the regeneration of alveolar bone relies 
on the differentiation of bone marrow mesenchymal stem cells (BMSCs) or periodontal ligament stem 
cells into osteoblasts, which are responsible for the formation of new bone [4,5]. Obviously, inducing 
and activating more osteoblasts can promote the regeneration of destroyed alveolar bone. To realize 
this aim, great efforts have been made to induce osteoblasts in vitro [1,6]. As the periodontal ligament 
cells are hard to culture, BMSCs, which can be easily isolated and cultured, are usually selected as the 
seed cells for generating osteoblasts in vitro [7]. To develop agents for preventing the loss of alveolar 
bone, rats like Wistar rat or Sprague-Dawley rat are often used as animal models because the 
periodontal anatomy in the molar region of the rats shares similarities with that of humans. By placing 
ligature in the gingival sulcus around the molar teeth, experimental periodontitis with alveolar bone 
loss could be readily induced in the rats [8–10].  
During the life of periodontium, the alveolar bone continuously remodels its shape in response to 
both the mechanical forces on the tooth and inflammation [11]. Growth and the modeling/remodeling 
of the alveolar bone are integral processes including multiple feedback loops between osteoblast and 
osteoclast [6,12]. The recruitment of new osteoclasts is dependent on the balance between the receptor 
activator of the NF-κB ligand (RANKL) and osteoprotegerin (OPG) in the osteoblasts [13,14]. The 
balance determines the formation and activity of osteoclasts. The activated osteoclasts comprise an 
integral component of bone destruction [15–17]. In addition to OPG and RANKL, runt-related 
transcription factor 2 (Runx2), Osterix and type I procollagen (collagen I) are also involved in bone 
formation [18–20]. Currently, the application of various regenerative biomaterials, such as bone 
autografts, allografts, cell occlusive barrier membranes used in guided tissue regeneration procedures, 
applications of bone morphogenetic protein (BMP) and growth factors (e.g., enamel matrix proteins), 
or their combinations, have been pursued with varying degrees of success to regenerate the lost tooth 
support [21,22]. However, these therapeutic strategies have been shown to be limited in the 
predictability of healing and in regenerative response in modern clinical practice.  
In the recent decade, synthesized single stranded oligodeoxynucleotide (ODN) has been 
demonstrated to modulate osteoblasts and osteoclasts. CpG containing oligodeoxynucleotides   Int. J. Mol. Sci. 2012, 13                 
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(CpG-ODNs) inhibit the activity of the physiological osteoclast differentiation factor RANKL in early 
osteoclast precursors (OCPs) but strongly stimulate osteoclastogenesis in cells primed by RANKL. The 
enhanced osteoclastogenic effect is mediated by TNF-α mediates by an autocrine mechanism [23,24]. 
The inhibitory effect could suggest the possibility of using CpG-ODNs to block pathological bone loss 
as in periodontitis [25]. The osteoclastogenic effect of CpG-ODN is dependent on activation of   
Toll-like receptor 9 (TLR9) as shown in TLR9-deficient (TLR9−/−) mice. Activation of TLR9 in bone 
marrow-derived osteoclast precursors is more crucial to induction of osteoclastogenesis than activation 
of the osteoblastic TLR9 [26]. The CpG ODN induced TLR9 signals are transmitted through ERK, p38 
and NFκB pathways which are inhibited by chloroquine, suggesting a requirement for endosomal 
maturation/acidification, the classic CpG ODN mode of action [27]. In addition to TNF-α, IL-12 
induced by CpG-ODN mediated TLR9 activation opposes RANKL-induced osteoclast differentiation [28]. 
In our preliminary studies, we found that MT01 [29], a synthetic single stranded ODN, whose design is 
based on human mitochondrial DNA, had a significant impact in facilitating osteogenic proliferation 
and activation. This provided direct evidence for the notion that single strand ODN could regulate the 
balance of bone formation and resorption, and thus was of great potential in the rebuilding of alveolar 
bone [30]. However, the effects of ODNs including MT01 on the proliferation and differentiation of 
BMSCs to osteoblasts have not been clearly elucidated. 
In this study, a batch of ODNs, whose design is based on the sequences in human microsatellite 
DNA and mitochondrion DNA and confirmed with immuno-stimulatory or immuno-inhibitory 
activities, were screened for their capacity to induce proliferation and differentiation of rat BMSCs. In 
the process, an ODN, designated as MT01, was found to strongly activate the differentiation of rat 
BMSCs in vitro and significantly reduce the alveolar bone loss in rats with periodontitis. 
2. Results and Discussion 
2.1. Screening of ODNs Capable of Stimulating the Proliferation and Differentiation of Rat BMSCs 
To detect the effects of ODNs on the proliferation of BMSCs, we selected and synthesized   
12 ODNs with different sequences using DNA synthesizer as described in the Experimental Section 
and tested them for their ability to stimulate the proliferation of rat BMSCs in vitro. These ODNs were 
designed based on the sequences in human microsatellite DNA and mitochondrion DNA and 
confirmed with immuno-stimulatory or immuno-inhibitory activities [29,31–34]. In the test, Wistar rat 
BMSCs at the third passage were cultured with a medium containing various ODNs at a final 
concentration of 1 μg/mL for 72 h. The proliferation of BMSCs was determined using MTT assay. As 
shown in Figure 1, four ODNs, designated as MT01, SAT05d, BW001 and FC004 were found to have 
the ability to stimulate the proliferation of all the rat BMSCs. The efficacy was significantly stronger 
than that induced by PBS (P < 0.05, n = 4).  Int. J. Mol. Sci. 2012, 13                 
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Figure 1. Effect of oligodeoxynucleotides (ODNs) with different sequences on the 
proliferation of rat bone marrow mesenchymal stem cells (BMSCs). The third passage 
BMSCs from three different rats were separately seeded in a 96-well-plate at 5 × 10
3/well 
and cultured in DMEM for 12 h. After adding ODNs (1 μg/mL, final concentration), the 
cells were cultured for 72 h and then subjected to MTT assay. OD570 value was used to 
express the cell proliferation (n = 4 per group). * Indicates statistically significant 
difference (P < 0.05) between experimental and control groups. 
0.8
1.0
1.2
1.4
1.6
1.8
 



 Rat 1
 Rat 2
 Rat 3
 Average
R
e
l
a
t
i
v
e
 
p
r
o
l
i
f
e
r
a
t
i
o
n
 
e
f
f
i
c
i
e
n
c
y
P
B
S
F
C
0
0
3
S
A
T
0
5
f
S
A
T
0
5
d
M
S
1
9
B
W
0
0
1
F
C
0
0
1
F
C
0
0
2
B
W
0
0
6
Y
W
0
0
2
Y
W
0
0
1
F
C
0
0
4
M
T
0
1
P < 0.05
P < 0.05
P < 0.05
P < 0.05

 
Figure 2. Effect of ODNs with different sequences on the expression of alkaline 
phosphatase (ALP) in rat BMSCs. (A) Screen of the ODNs (n = 6 per group); (B) Dose 
effect of the ODNs (n = 6 per group); (C) Kinetic effect of the ODNs. * Indicates 
statistically significant difference (P < 0.05) between MT01 and PBS; ** Indicates 
statistically significant difference (P < 0.01) between MT01 and PBS. 
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Figure 2. Cont. 
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Accumulating studies showed that BMSCs could be induced to differentiate into osteogenic cells. 
To observe whether the ODNs could also impact the osteoblast differentiation from BMSC, rat 
BMSCs, cultured to passage 3, were seeded to 12 well plate (2 × 10
4 cells per well) in 1000 μL 
complete DMEM with osteogenic media and then cultured for 24 h. After adding the 12 ODNs   
(1 μg/mL, final concentration) separately, the cells were cultured for another 72 h and then tested for 
their expression of alkaline phosphatase (ALP), a marker for the early stage differentiation of 
osteoblasts. As shown in Figure 2A, MT01, FC001, YW002, YW001 and FC004 could strongly 
stimulate the differentiation of rat BMSCs to osteoblasts. Based on this, the five ODNs were selected 
to test their dose-effect on the differentiation dynamically. As described above, the BMSCs at passage 
3 were cultured with MT01, FC001, YW002, YW001 or FC004 at a dose range of 0.5, 1, 2 and  
4 μg/mL(final concentration), respectively, and then assayed for their ALP activity. It was found that 
MT01 at 2 μg/mL, 1 μg/mL and 0.5 μg/mL, but not at 4 μg/mL, could induce significant expression of 
ALP (Figure 2B). Next, the five ODNs were tested for their promotion on the differentiation Int. J. Mol. Sci. 2012, 13                 
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kinetically. The BMSCs at passage 3 were cultured with each of the ODNs at 1 μg/mL (final 
concentration) for 24, 72 or 120 h, respectively, and then assayed. The results showed that MT01 and 
FC004 could significantly induce ALP expression at three time-points (Figure 2C). Overall, the dose 
and kinetic analysis showed that MT01 was the best candidate ODN to induce the differentiation from 
BMSCs to osteoblasts. 
2.2. MT01 Induces the Differentiation of BMSCs to Osteoblasts and Its Possible Mechanism 
From the above results, we selected MT01 to study the possible mechanism underlying its effect on 
inducing the differentiation of BMSCs to osteoblast. As reported, MT01 (5′-ACC CCC TCT ACC 
CCC TCT ACC CCC TCT-3′), a 27-mer ODN, was synthesized with reference to human mitochondrial 
DNA. Functionally, MT01 is able to inhibit the proliferation of human peripheral blood mononuclear 
cells (PBMCs) induced by CpG-ODNs and the production of type I interferon (IFN) from human 
PBMCs stimulated by TLR agonists, including inactivated influenza virus, imiquimod, inactivated 
herpes simplex virus-1 (HSV-1) and CpG ODNs. Presumably, the MT01 could be a biological candidate 
with therapeutic use in TLR activation associated diseases [29]. To investigate the role of MT01 on the 
differentiation of BMSCs to osteoblast and its possible mechanism, using quantitative real-time PCR, 
we detected the effects of MT01 on inducing mRNA expression of bone-related factors including 
RANKL, OPG, Runx2, Osterix and collagen I in BMSCs. The expression of these genes was confirmed 
to be related to osteoblastogenesis and was required for the osteoblast differentiation [35–37]. 
Figure 3. MT01 induced mRNA expression in BMSCs. Rat BMSCs were stimulated with 
MT01 (1 μg/mL) or PBS for 1, 3 or 5 days. The mRNA expression of the genes related to 
osteoblastogenesis was detected using quantitative real-time PCR. (A) RANKL mRNA 
expression; (B) OPG mRNA expression; (C) Ratio of RANKL to OPG mRNA expression; 
(D) Runx2 mRNA expression; (E) Osterix mRNA expression; (F) Collagen I mRNA 
expression.  β-Actin was used as the internal reference. Data from one representative 
experiment of three are shown. 
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Figure 3. Cont. 
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In the detection, BMSCs at the third passage were cultured with MT01 at 1 μg/mL (final 
concentration) for 1, 3 or 5 days, respectively, and their mRNAs were isolated for real-time PCR 
analysis. The results showed that stimulation with MT01 for 3 or 5 days induced BMSCs to express 
significantly increased mRNA level of RANKL and OPG (P < 0.01) (Figure 3A,B). Noticeably, the 
mRNA ratio of RANKL/OPG gradually decreased from 1 to 5 days (Figure 3C). Meanwhile, mRNA 
levels of Runx2, Osterix and collagen I were increasingly induced by MT01 for 3 and 5 days (P < 0.01 
or P < 0.05) (Figure 3D–F). In conclusion, ODN MT01 could significantly promote the differentiation 
of rat BMSCs to osteoblastic cells and enhance the osteoblast activity, possibly by inducing the   
up-regulation of Runx2, Osterix, OPG, RANKL and collagen I in the BMSCs. 
2.3. MT01 Mediated Reduction of Alveolar Bone Loss in Experimental Periodontitis Rats  
The purpose of this study was to find the active substance capable of promoting the osteoblastic 
differentiation of BMSCs, with a potential to be used in tissue repairing and alveolar bone regeneration. 
To further test whether MT01 could promote the alveolar bone regeneration in vivo, we firstly 
established a rat model of experimental periodontitis using the silk ligation method [8,9]. Immediately 
after the ligation, the rats were injected once with MT01 (20 μg/kg) into the local periodontal tissue. 
On days 3, 5, and 7 after the ligation, the rats received three more injections of MT01 (20 μg/kg), Int. J. Mol. Sci. 2012, 13                 
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respectively. Two or four weeks later, after the ligation, the rats were sacrificed for detecting 
immunohistochemical changes and alveolar bone loss. 
The alveolar bone loss was determined by measuring the distance from the amelocemental junction 
to the alveolar crest. The results showed that the absorption of alveolar bone had no significant 
difference between the MT01 treated rats and PBS treated rats at 2 weeks. However, at 4 weeks after the 
ligation, the absorption of alveolar bone, especially of palatal bone, in the MT01 treated rats was 
dramatically reduced compared to that in the PBS treated rats (P < 0.05) (Figure 4A,B). Through 
analysis of the extent of alveolar bone loss, it could be concluded that MT01 could prevent alveolar 
bone loss. 
Figure 4. Influence of MT01 on alveolar bone loss in rat with periodontitis. Macroscopic 
aspects (Lingual and Buccal view) of the mandibles were observed. The yellow lines 
represented the distance from the amelocemental junction to the alveolar crest. (A) Analysis 
of the alveolar bone loss by SPOT RT software v3.5 [38,39]; (B) The extent of alveolar 
bone loss showed in the change of measurement between the control and MT01 treatment 
groups where n = 3 per group. * Indicates statistically significant difference (P < 0.05) 
between MT01 and PBS. ** Indicates statistically significant difference (P < 0.01) between 
MT01 and PBS. 
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Immunohistochemical detection (Figure 5) showed that MT01 treatment did not elevate the 
production of RANKL, Runx2 and collagen I proteins in the alveolar bone tissue collected in 4 weeks. 
Notably, MT01 treatment induced much more OPG expressing and Osterix expressing cells in the 
tissue. The results demonstrated that MT01 mediated prevention of alveolar bone absorption in the rat 
with periodontitis was associated with OPG and Osterix production. 
Figure 5. Effect of MT01 on the production of proteins of bone-associated factors. In the 
sections of the alveolar bone, RANKL (A), OPG (B), Runx2 (C), Osterix (D) and collagen 
I (E) producing cells were recognized by their specific antibodies, respectively.   
The positive cells were analyzed statistically and shown in F. Data were expressed by 
mean ± SD of 6 rats each group (* P < 0.05; ** P < 0.01, compared with the PBS group). 
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3. Experimental Section 
3.1. Materials 
The ODNs were synthesized by TaKaRa (Dalian, China). The sequences of ODNs were as follows: 
FC003 (5′-TCT CTC TCT CTC TCT CTC TCT CTC-3′), SAT05f (5′-CCT CCT CCT CCT CCT CCT 
CCT CCT-3′) [29], SAT05d (5′-CTC TCT CTC TCT CTC TCT CTC TCT-3′) [29], MS19   
(5′-AAA GAA AGA AAG AAA GAA AGA AAG-3′) [32], BW001 (5′-TCG TCG GGT GCG ACG 
TCG CAG GGG GG-3′) [31], FC001 (5′-TCG GGG ACG ATC GTC GGG GGG-3′) [33], FC002  
(5′-TCG TCG ACG TCG TTC GTT CTC-3′) [34], BW006 (5′-TCG ACG TTC GTC GTT CGT CGT 
TC-3′) [33], YW002 (5′-TCG CGA ACG TTC GCC GCG TTC GAA CGC GG-3′) [32], YW001  
(5′-TCG CGA CGT TCG CCC GAC GTT CGG TA-3′) [34], FC004 (5′-TCG CGA ACG TTC GCC 
CGA TCG TCG GTA-3′) [31] and MT01 (5′-ACC CCC TCT ACC CCC TCT ACC CCC TCT-3′) [29]. 
All ODNs were diluted using PBS buffer, and no endotoxins were detected (Limulus amebocyte lysate 
assay, Associates of Cape Cod, Inc.). All the reagents used in the research were pyrogen-free. 
3.2. Isolation, Culture and Identification of BMSCs 
One-month rats were sacrificed by cervical dislocation, and sterilized with alcohol of 0.75 volume 
fraction for 10 min. The femur and tibia were removed, and the osteoepiphysis was sheared off. The 
bone marrow was collected using a syringe with 5 mL of serum-free DMEM. The suspension was 
transferred into a centrifuge tube, blown and centrifuged at 1000 r/min for 5 min. After discarding the 
supernatant and adipose layer, 5 mL DMEM containing 10% fetal calf serum was added to   
re-suspend the cells. The cells at density of 1 × 10
9 L
−1 were inoculated in a 25 cm
2 culture flask and 
cultured at 37 °C in the 5% CO2 incubator at saturated humidity. After 48 h, half of the medium was 
removed and replaced with fresh medium. The cells were further cultured for 3 days, and then the 
medium was completely replaced to remove the non-adherent cells. Afterwards, the medium was 
completely replaced every 3 days. The cells were observed under an inverted microscope daily. When 
80–90% confluence was achieved, the cells were digested with 0.25% trypsin containing 0.02% EDTA 
and passaged at a ratio of 1:2. The cells at the third passage were harvested to prepare the single cell 
suspension and then identified by staining with phyco-erithrin conjugated antibodies (Sangon Biotech., 
Shanghai, China) against CD34, CD44, CD45, CD90 and CD116, respectively, and analyzed on a 
FACS caliber (Becton Dickinson, San Jose, CA, USA) using Cell Quest software with 10,000 events 
collected for each sample. The identified CD45, CD90 and CD116 positive cells were used as   
BMSCs [40]. 
3.3. Proliferation Assay  
Proliferation of BMSCs was determined using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay as previously described [41]. Briefly, 5 × 10
3 cells/well in 200 μL DMEM 
containing 10% fetal calf serum were inoculated into 96-well plates and cultured with medium 
containing various ODNs at a final concentration of 1 μg/mL. The cells were incubated at 37 °C for  
72 h, and 10 μL of MTT solution (5 mg/mL) was added, followed by incubating for another 4 h. Int. J. Mol. Sci. 2012, 13                 
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Finally, the supernatant was removed, and cells were lysed with 150 μL DMSO. The absorbance at 
570 nm of each well was measured using a Bio RAD 550 automatic plate reader.  
3.4. ALP Analysis in BMSCs 
BMSCs at 2 × 10
4 cells/well at the third passage were cultured in 1000 μL DMEM containing 10% 
fetal calf serum in a 24-well plate for 24 h, and then the medium was completely replaced with fresh 
medium with a 1% osteogenesis inducing solution containing 10 mmol/L β-glycerin phosphoric acid, 
0.05 mmol/L vitamin C and 100 mmol/L dexamethasone in PBS. After the addition of ODNs at a final 
concentration of 1 μg/mL, the cells were cultured for 72 h, and washed with PBS twice. The washed 
cells were lysed at 0 °C for 30 min. Total protein concentration and ALP activity in the cell lysate were 
measured using a micro-BCA assay kit (Jiancheng Biological Reagent Co., Nanjing, China) and an 
alkaline phosphatase kit (Jiancheng Biological Reagent Co., Nanjing, China) according to the 
manufactures’ instructions, respectively. The average ALP activity of triplicate measurements was 
normalized with the reference of total protein concentration. 
3.5. Quantitative Real-Time PCR 
Total RNA was isolated from BMSCs using the Trizol reagent (Sigma, St. Louis, MO, USA) 
according to the manufacturer’s instructions. The purity of total RNA was determined by the ratio at 
260 nm and 280 nm absorbance. Using RT-PCR Array First Strand Kit (SA Bioscience Co., Carlsbad, 
CA, USA), 1 μg of total RNA was reverse-transcribed into total cDNAs. The cDNAs were subjected to 
PCR amplification by using specific primers as follows: RANKL (F: 5′-CTG ATG AAA GGA GGG 
AGC AC-3′; R: 5′-GAA GGG TTG GAC ACC TGA ATG C-3′), OPG (F: 5′-TCC TGG CAC CTA 
CCT AAA ACA GCA-3′; R: 5′-ACA CTG GGC TGC AAT ACA CA-3′), Osterix (F: 5′-CCT CTC 
GAC CCG ACT GCA GAT C-3′; R: 5′-AGC TGC AAG CTC TCT GTA ACC ATG AC-3′), Runx2 
(F: 5′-TGC TTC ATT CGC CTC ACA AA-3′; R: 5′-TTG CAG TCT TCC TGG AGA AAG TT-3′ ) 
and collagen I (F: 5′-GAG ATG ATG GGG AAG CTG-3′; R: 5′-ACC ATC CAA ACC ACT GAA G-3′). 
In each sample, the specific primers of β-actin (F: 5′-TCA GGT CAT CAC TAT CGC CAA T-3′;  
R: 5′-AAA GAA AGG GTG TAA AAC GCA-3′) were used as an internal reference and 
simultaneously amplified. Efficiencies (E) of amplicons in the PCRs were determined by dilution 
curves, and used to calculate the relative quantification values for each target cDNA. The PCRs were 
performed using an ABI PRISM 7000 detection system under the conditions as follows: 50 °C for  
2 min, 95 °C for 10 min, 45 cycles of 95 °C for 15 s, and 60 °C for 1 min. The cycle threshold (Ct) was 
established in the linear part of the reaction curve at which the amount of amplified target cDNA was 
calculated. The relative expression levels of a target gene were normalized with the value of β-actin 
gene, and the 2
−ΔΔCt  method [42] was used for calculating the relative expression levels. The values 
were the average of triplicate measurements.  
3.6. Rat Experiment 
Six-week-old specific pathogen-free (SPF) male Wistar rats (180–210 g body weight) were 
purchased from Animal Center of Norman Bethune Medical College, Jilin University (Changchun) and Int. J. Mol. Sci. 2012, 13                 
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maintained in laminar flow rooms and used for experiments in accordance with the National Institute 
of Health Guide for the Care and Use of Laboratory Animals, and with the approval of the Scientific 
Investigation Board of Science and Technology of Jilin Province. To establish a periodontitis model, 
rats were intramuscularly anesthetized with 0.8 mL/kg body weight of Su-Mian-Xin (Veterinary 
Institute of Military Supplies University, Changchun, China), composed of dihydroetorphine 
hydrochloride, dimethylaniline thiazole, EDTA and haloperidol. Sterile, 3–0 black braided nylon 
thread (surgilon; USS/DG, Norwalk, CT, USA) was placed around the cervical margins of the bilateral 
second maxillary molars and knotted mesially. The ligature was knotted on the buccal side of the tooth, 
resulting in a subgingival position palatal and a supragingival position buccally, as previously 
described [43].  
On days 0, 3, 5, and 7 after the ligature placement, the rats were injected with MT01 (20 μg/kg) or 
PBS in the gingiva of the left and right second maxillary molars, respectively. At 2 and 4 weeks after 
the ligature placement, 6 rats in each group were euthanized. One side of the maxillary of the rats was 
removed and stored at −80 °C for routine histological examination, and the other side was stored at 
−20 °C for measuring its alveolar bone loss.  
3.7. Microscopic Examination of Alveolar Bone Loss 
To measure the alveolar bone loss, frozen maxillaries were thawed, de-fleshed by 2 N NaOH for  
10 min, then washed and air dried. Each maxillary was fixed with white wax in an orientation to make 
buccal and lingual cusps, superimposed for taking photos using a Stereoscope (Stemi SV 11; Zeiss, 
Oberkochen, Germany) equipped with a videocamera (Axio-Cam HRc; Zeiss) and a TV monitor, 
which displayed the distance digitally. The photos were analyzed by SPOT RT software v3.5 [38,39]. 
To reduce the possible errors caused by the projection angle, a graduated periodontal probe was 
photographed alongside the maxillaries. The distances from the amelocemental junction to the alveolar 
crest were recorded six times per tooth. The average distance (expressed in mm) for each tooth was 
used as a measurement of bone loss. The sensitivity of the measurement was ca. 10. These 
measurements were repeated three times at one week intervals. The average coefficient of variation for 
the measurements was 1.53%. 
3.8. Immunohistochemistry of RANKL, OPG, Osterix, Runx2 and Collagen I 
Thin sections of periodontal tissue (5 μm) were obtained by using a microtome and transferred to a 
gelatin coated slide. The tissue section was first deparaffinized and then rehydrated. The gingival and 
periodontal tissue slices, after washing with 0.3% Triton X-100 in phosphate buffer, and quenching of 
endogenous peroxidase (3% hydrogen peroxide), were incubated with primary antibody (RANKL 
1:250, or OPG 1:250, or Runx2 1:250, or Osterix 1:250, or collagen I 1:250) overnight at 4 °C. After 
washing with phosphate buffer, the slices were incubated with secondary antibody for 1 h, the 
immuno-reactivity to RANKL, OPG, Osterix, Runx2 and collagen I was visualized using a 
colorimetric-based detection kit following the manufacturer’s protocol (Dako LSAB + Kit, peroxidase, 
DAKO, Carprinteria, CA, USA). The positive cells expressing RANKL, OPG, Osterix, RunX2 or 
collagen I were numerated under a microscope (Olympus Optical Co. Ltd, Tokyo, Japan) using 200× 
objective in a double-blind manner. The results were presented as mean numbers of cell/field, which Int. J. Mol. Sci. 2012, 13                 
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were obtained by counting nine randomly selected microscopic fields (0.006 mm
2/each) with the 
gingival tissue between the first and second molars.  
3.9. Statistical Analysis 
All data were presented as the mean ± SD. The significance of the differences was determined using 
the two-tailed Student’s t test and one-way ANOVA. For each figure, representative results from  
2–3 independent experiments were exhibited.  
4. Conclusions  
In this study, MT01, a synthetic ODN, designed with the reference of the sequence of human 
mitochondrial DNA, has been shown to be able to induce differentiation of BMSCs to osteoblasts  
in vitro and prevent alveolar bone absorption in rats with periodontitis. The data suggest that MT01 
could be developed as a candidate agent for the treatment of periodontitis by reducing alveolar 
bone  absorption.  
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